Astec Lifesciences Ltd
Thu 13/03/2025,15:59:8 | NSE : ASTEC
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 697.50
Previous Close
₹ 692.35
Volume
75866
Mkt Cap ( Rs. Cr)
₹1282.39
High
₹ 707.45
Low
₹ 650.00
52 Week High
₹ 1474.40
52 Week Low
₹ 647.50
Book Value Per Share
₹ 148.64
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Astec Lifesciences Ltd
Your Vote -
Buy
62.50%
Hold
25.00%
Sell
12.50%
62.50%
16 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
653.90
7
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
7
Option Chain
Analyzes market sentiment, predicts Astec Lifesciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Astec Lifesciences L - Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 Regarding Sale Of Vacant Office Premi
-
Astec Lifesciences L - General Updates
-
Astec Lifesciences L - Reply to Clarification- Financial results
-
Astec Lifesciences L - Clarification - Financial Results
-
Astec Lifesciences L - Copy of Newspaper Publication
-
Astec Lifesciences L - Integrated Filing (Financial)
-
Astec Lifesciences L - Integrated Filing- Financial
-
Astec Lifesciences L - Notice Of Shareholders Meetings-XBRL
-
Astec Lifesciences L - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Astec Lifesciences L - Shareholders meeting
-
Astec Lifesciences L - Copy of Newspaper Publication
-
Astec Lifesciences L - Acquisition-XBRL
-
Astec Lifesciences L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Astec Lifesciences L - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Astec Lifesciences L - Press Release
-
Astec Lifesciences L - Others
-
Astec Lifesciences L - Intimation Of Proposed Acquisition Of 26% Equity Shareholding In Proposed Special Purpose Vehicle
-
Astec Lifesciences L - Re-Appointment Of Independent Director
-
Astec Lifesciences L - Intimation Of Grant Of Stock Options
-
Astec Lifesciences L - General Updates
-
Astec Lifesciences L - Intimation For Conduct Of Postal Ballot For Seeking Approval Of The Shareholders For Re-Appointment Of
-
Astec Lifesciences L - General Updates
-
Astec Lifesciences L - Appointment
-
Astec Lifesciences L posts Q3 net loss of Rs 40.40 cr
-
Astec Lifesciences L - Outcome Of The Board Meeting Held On Monday, 27Th January, 2025
-
Astec Lifesciences L - Financial Result Updates
-
Astec Lifesciences L - Outcome of Board Meeting
-
Astec Lifesciences L - Outcome of Board Meeting
-
Astec Lifesciences L - Announcement under Regulation 30 (LODR)-Acquisition
-
Astec Lifesciences L - Announcement under Regulation 30 (LODR)-Change in Directorate
-
Astec Lifesciences L - Board Meeting Outcome for Outcome Of The Board Meeting Held On Monday, 27Th January, 2025
-
Astec Lifesciences L - Board Meeting Intimation
-
Astec Lifesciences L - Board Meeting Intimation for Intimation Of Board Meeting For Approving The Standalone And Consolidated
-
Astec Lifesciences L has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Astec Lifesciences L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Astec Lifesciences L - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Astec Lifesciences L - Updates
-
Astec Lifesciences L - Updates on Open Offer
-
Astec Lifesciences L - General Updates
-
Astec Lifesciences L - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And
-
Astec Lifesciences L - Spurt in Volume
-
Astec Lifesciences L - Spurt in Volume
-
Astec Lifesciences L - Trading Window-XBRL
-
Astec Lifesciences L - Trading Window
-
Astec Lifesciences L - General Updates
-
Astec Lifesciences L - Intimation Of Appointment Of Senior Management Personnel
-
Astec Lifesciences L - Shareholders meeting
Key fundamentals
Evaluate the intrinsic value of Astec Lifesciences Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 862.5712 | 759.9738 | 675.3541 | 495.7336 | 345.1506 |
Liabilities | 862.5712 | 759.9738 | 675.3541 | 495.7336 | 345.1506 |
Equity | 19.6092 | 19.6057 | 19.5976 | 19.5876 | 19.5684 |
Gross Profit | -5.9027 | 76.265 | 154.0835 | 111.5063 | 85.2043 |
Net Profit | -46.9871 | 25.5204 | 89.818 | 64.6925 | 47.4719 |
Cash From Operating Activities | 10.1314 | 74.3232 | 23.412 | -8.0619 | 168.5612 |
NPM(%) | -10.25 | 4.06 | 13.27 | 11.65 | 9.09 |
Revenue | 458.1807 | 628.1662 | 676.5661 | 554.8721 | 522.2209 |
Expenses | 464.0834 | 551.9012 | 522.4826 | 443.3658 | 437.0166 |
ROE(%) | -16.11 | 8.75 | 30.81 | 22.19 | 16.28 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
21 Jul 2023 | 1.5 | 15 | 0 | 1351.65 |
19 Jul 2022 | 1.5 | 15 | 0 | 1950.65 |
22 Jul 2021 | 1.5 | 15 | 0 | 1156.65 |
16 Jul 2020 | 1.5 | 15 | 0 | 435.35 |
18 Jul 2019 | 1.5 | 15 | 0 | 507.05 |
19 Jul 2018 | 1.5 | 15 | 0 | 691.25 |
17 Jul 2017 | 1.5 | 15 | 0 | 596.25 |
15 Sep 2015 | 1.25 | 12.5 | 0 | 165.5 |
15 Sep 2014 | 1 | 10 | 0 | 43.3 |
02 Sep 2013 | 0.75 | 7.5 | 0 | 18.55 |
13 Sep 2012 | 0.5 | 5 | 0 | 25.05 |
15 Sep 2011 | 0.5 | 5 | 0 | 46.8 |
12 Aug 2010 | 1 | 10 | 0 | 57.35 |
Peers
Other companies within the same industry or sector that are comparable to Astec Lifesciences Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 373.76 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 1361.95 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 702.00 | 2.31 | 0.00 |
Suraksha Diagnostic Ltd | 278.10 | 7.02 | 46.51 | 45.19 | 226.82 | 0.00 |
Company Info
Our Company was incorporated on January 25, 1994 under the Companies Act, 1956 as Urshila Traders Private Limited. Our Company was originally promoted by Mrs. Reena Bagai and Mrs. Avita Fernandes. Their shareholding was purchased by Mr. Ashok V Hiremath and Mr. Pratap Garud on February 11, 1994. The name of our Company was changed to Astec Chemicals Private Limited on August 19, 1994 and further to Astec LifeSciences Private Limited on March 3, 2006. With effect from April 27, 2006, Astec LifeSciences Private Limited was converted into a public limited company under the name of "Astec LifeSciences Limited". We carry out our manufacturing activities at two locations in Maharashtra, India comprising of three units in Maharashtra viz. one unit at Dombivli and two units at Mahad (Unit 1 and Unit 2). We started our first manufacturing unit in August 1994 by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. With a view to expand our operations, we entered into an agreement with Behram Chemicals Private Limited on February 18, 2002 for using and operating their manufacturing facilities located at B-16, Mahad Industrial Area, Sub-District Mahad, District Raigad, Maharashtra. Behram Chemicals Private Limited was engaged in manufacture of chemicals and pesticides having an installed capacity of 130 MT. Behram Chemicals Private Limited was initially promoted by Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma in April, 1993. During August, 1998 further shares were allotted to M.C. Chemicals and some members of Gangani family viz. Mr. Nasrudin K Gangani, Mr. S. N. Gangani, Mrs. N. N. Gangani, Mr. T. K. Gangani and Khoja Bone Mills Private Limited (a company promoted by Gangani family). Looking at the potential in Behram Chemicals Private Limited, our Company have acquired 65.63% share by entering into Share Purchase Agreement with the above members of Gangani family on April 2, 2007. Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma, M.C. Chemicals and Gangani family are not related to our Promoters / our Directors in any manner in any capacity whatsoever. With this acquisition, Behram Chemicals Private Limited became a subsidiary of our Company. During 2003-04 we expanded total installed capacity of our units (Dombivli and Mahad) from 250 MT to 500 MT. We renewed the agreement on August 1, 2004 for a further period of 66 months ending on January 31, 2010. For more details in respect of the current agreement. In 2004, we acquired a plot located at B-17, Mahad, Maharashtra and set up a new manufacturing facility as an Export Oriented Unit (EOU) in the year 2005 (as Unit 2) which is located adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2 our total installed capacity increased to 1500 MT. We further expanded our total capacities to 2000 MT during 2006- 07 and to 2500 MT during 2007-08. Our Company is primarily involved in the production of active ingredients and intermediates for agrochemicals and pharmaceutical segment. Hexaconazole, Tebuconazole, Metalaxyl and Propiconazole are some of our key products in agrochemical segment which are generally used in crop protection and Dicap is one of our key Pharmaceutical intermediate which is used in manufacture of antifungal agents. Triazole fungicides, which includes Hexaconazole, Tebuconazole, and Propiconazole is one of our major product in the agrochemical segment, and has contributed 63.67% to our total sales whereas Dicap, a key product in pharmaceutical segment has contributed 9.01% during FY 2007-08. Major events of our Company Period Events January 1994 Incorporation of Urshila Traders Private Limited August 1994 Change of name to Astec Chemicals Private Limited August 1994 Commenced first manufacturing unit at Dombivli, Maharashtra May, 2001 Certified ISO 9002 by International Standards Certification Pty Limited, Australia February 2002 Entered into an agreement with Behram Chemicals Private Limited March 2005 Re-certified ISO 9001:2000 by International Standards Certification Pty Limited, Australia May 2005 Commenced another manufacturing unit (Unit 2) as Export Oriented Unit at Mahad, Maharashtra March 2006 Change of name to Astec LifeSciences Private Limited April 2006 Conversion of our Company from a private limited company to a public limited company January 2007 Established Astec Europe in Tournai, Belgium April 2007 Behram Chemicals Private Limited became our subsidiary by acquisition of 65.63% vide Share Purchase Agreement dated April 2, 2007 2011 -Registered Office of the Company has been shifted 5, 5-A, 4th Floor, Kamanwala Chambers, Sir P. M. Road, Fort, Mumbai - 400001 To Elite Square, 7th Floor, 274, Perin Nariman Street, Fort, Mumbai - 400001. 2012 - Astec has entered into an exclusive long term contract with a multinational company to manufacture and supply a fungicide - Astec Recommended a dividend of fifty paise per share (i.e. 5% on the face value of Rs.10/- each) 2013 -Astec Lifesciences Ltd has Recommended a dividend of Seventy Five paise per share (i.e. 7.5% on face value of Rs. 10/- each). -Mr. Ravindra Inani as Chief Financial Officer (CFO) of the Company. 2014 -Appointed Dr. Leena Raje as the new Woman Director. -Astec Lifesciences Ltd has recommend enhanced dividend of Rupee One per share (i.e. 10% on the face value of Rs. 10/- each. 2017 -Astec Lifesciences Ltd was received Certificate of Merit for Performance in Industrial Safety 2017 2018 -Astec Lifesciences Ltd Wins Indian Chemical Council (ICC) Award For Excellence In Management --Astec Lifesciences Ltd amalgametted with Godrej Agrovet Limited 2019 -Astec Lifesciences Ltd was awared ICC Award for Excellence in Human Resource Management 2020 -Astec Lifesciences Ltd is stake entire equity in Astec Europe Sprl 2021 -Astec LifeSciences Limited commenced commercial production at its new Herbicide plant at Mahad 2023 -Astec LifeSciences launches Rs. 100 crore Adi Godrej Center for Chemical Research and Development. -Astec LifeSciences launches R&D Center to develop new crop protection formulations.
Our Company was incorporated on January 25, 1994 under the Companies Act, 1956 as Urshila Traders Private Limited. Our Company was originally promoted by Mrs. Reena Bagai and Mrs. Avita Fernandes. Their shareholding was purchased by Mr. Ashok V Hiremath and Mr. Pratap Garud on February 11, 1994. The name of our Company was changed to Astec Chemicals Private Limited on August 19, 1994 and further to Astec LifeSciences Private Limited on March 3, 2006. With effect from April 27, 2006, Astec LifeSciences Private Limited was converted into a public limited company under the name of "Astec LifeSciences Limited". We carry out our manufacturing activities at two locations in Maharashtra, India comprising of three units in Maharashtra viz. one unit at Dombivli and two units at Mahad (Unit 1 and Unit 2). We started our first manufacturing unit in August 1994 by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. With a view to expand our operations, we entered into an agreement with Behram Chemicals Private Limited on February 18, 2002 for using and operating their manufacturing facilities located at B-16, Mahad Industrial Area, Sub-District Mahad, District Raigad, Maharashtra. Behram Chemicals Private Limited was engaged in manufacture of chemicals and pesticides having an installed capacity of 130 MT. Behram Chemicals Private Limited was initially promoted by Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma in April, 1993. During August, 1998 further shares were allotted to M.C. Chemicals and some members of Gangani family viz. Mr. Nasrudin K Gangani, Mr. S. N. Gangani, Mrs. N. N. Gangani, Mr. T. K. Gangani and Khoja Bone Mills Private Limited (a company promoted by Gangani family). Looking at the potential in Behram Chemicals Private Limited, our Company have acquired 65.63% share by entering into Share Purchase Agreement with the above members of Gangani family on April 2, 2007. Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma, M.C. Chemicals and Gangani family are not related to our Promoters / our Directors in any manner in any capacity whatsoever. With this acquisition, Behram Chemicals Private Limited became a subsidiary of our Company. During 2003-04 we expanded total installed capacity of our units (Dombivli and Mahad) from 250 MT to 500 MT. We renewed the agreement on August 1, 2004 for a further period of 66 months ending on January 31, 2010. For more details in respect of the current agreement. In 2004, we acquired a plot located at B-17, Mahad, Maharashtra and set up a new manufacturing facility as an Export Oriented Unit (EOU) in the year 2005 (as Unit 2) which is located adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2 our total installed capacity increased to 1500 MT. We further expanded our total capacities to 2000 MT during 2006- 07 and to 2500 MT during 2007-08. Our Company is primarily involved in the production of active ingredients and intermediates for agrochemicals and pharmaceutical segment. Hexaconazole, Tebuconazole, Metalaxyl and Propiconazole are some of our key products in agrochemical segment which are generally used in crop protection and Dicap is one of our key Pharmaceutical intermediate which is used in manufacture of antifungal agents. Triazole fungicides, which includes Hexaconazole, Tebuconazole, and Propiconazole is one of our major product in the agrochemical segment, and has contributed 63.67% to our total sales whereas Dicap, a key product in pharmaceutical segment has contributed 9.01% during FY 2007-08. Major events of our Company Period Events January 1994 Incorporation of Urshila Traders Private Limited August 1994 Change of name to Astec Chemicals Private Limited August 1994 Commenced first manufacturing unit at Dombivli, Maharashtra May, 2001 Certified ISO 9002 by International Standards Certification Pty Limited, Australia February 2002 Entered into an agreement with Behram Chemicals Private Limited March 2005 Re-certified ISO 9001:2000 by International Standards Certification Pty Limited, Australia May 2005 Commenced another manufacturing unit (Unit 2) as Export Oriented Unit at Mahad, Maharashtra March 2006 Change of name to Astec LifeSciences Private Limited April 2006 Conversion of our Company from a private limited company to a public limited company January 2007 Established Astec Europe in Tournai, Belgium April 2007 Behram Chemicals Private Limited became our subsidiary by acquisition of 65.63% vide Share Purchase Agreement dated April 2, 2007 2011 -Registered Office of the Company has been shifted 5, 5-A, 4th Floor, Kamanwala Chambers, Sir P. M. Road, Fort, Mumbai - 400001 To Elite Square, 7th Floor, 274, Perin Nariman Street, Fort, Mumbai - 400001. 2012 - Astec has entered into an exclusive long term contract with a multinational company to manufacture and supply a fungicide - Astec Recommended a dividend of fifty paise per share (i.e. 5% on the face value of Rs.10/- each) 2013 -Astec Lifesciences Ltd has Recommended a dividend of Seventy Five paise per share (i.e. 7.5% on face value of Rs. 10/- each). -Mr. Ravindra Inani as Chief Financial Officer (CFO) of the Company. 2014 -Appointed Dr. Leena Raje as the new Woman Director. -Astec Lifesciences Ltd has recommend enhanced dividend of Rupee One per share (i.e. 10% on the face value of Rs. 10/- each. 2017 -Astec Lifesciences Ltd was received Certificate of Merit for Performance in Industrial Safety 2017 2018 -Astec Lifesciences Ltd Wins Indian Chemical Council (ICC) Award For Excellence In Management --Astec Lifesciences Ltd amalgametted with Godrej Agrovet Limited 2019 -Astec Lifesciences Ltd was awared ICC Award for Excellence in Human Resource Management 2020 -Astec Lifesciences Ltd is stake entire equity in Astec Europe Sprl 2021 -Astec LifeSciences Limited commenced commercial production at its new Herbicide plant at Mahad 2023 -Astec LifeSciences launches Rs. 100 crore Adi Godrej Center for Chemical Research and Development. -Astec LifeSciences launches R&D Center to develop new crop protection formulations.
Read More
Parent Organisation
Astec Lifesciences Ltd.
Founded
25/01/1994
Managing Director
Mr.Nadir B Godrej
NSE Symbol
ASTECEQ
FAQ
The current price of Astec Lifesciences Ltd is ₹ 653.90.
The 52-week high for Astec Lifesciences Ltd is ₹ 707.45 and the 52-week low is ₹ 650.00.
The market capitalization of Astec Lifesciences Ltd is currently ₹ 1282.39. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Astec Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Astec Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Astec Lifesciences Ltd shares.
The CEO of Astec Lifesciences Ltd is Mr.Nadir B Godrej, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.